Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

fuconojirimycin

Known as: fuco-nojirimycin 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Tumor hypoxia is a major mechanism of resistance to radiation therapy (RT), which is associated with poor prognosis in affected… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
The present investigation was aimed at exploring the targeting potential of sulfasalazine (NF-κB inhibitor drug) loaded fucose… Expand
2013
2013
ABSTRACTPurposeTo develop, characterize and exploring the sulfasalazine loaded fucoyslated multi walled carbon nanotubes for… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2006
2006
BACKGROUND Platelet-endothelial interactions have been shown to be main mediators of leukocyte-independent endothelial damage… Expand
2006
2006
An efficient method for examining the selectivity of inhibitors on two alpha-fucosidases, one from Thermotoga maritima and the… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2004
2004
SummaryIn Escherichia coli the six known genes specifying the utilization of l-fucose as carbon and energy source cluster at 60.2… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2004
2004
Glycosidase inhibitors have shown great medicinal and pharmaceutical values as exemplified by the therapeutic treatment of… Expand
Highly Cited
2003
Highly Cited
2003
Polyhydroxypiperidines and pyrrolidines (also called iminocyclitols or aza-sugars) have attracted increasing attention because of… Expand
Highly Cited
2002
Highly Cited
2002
We report the fine structure of a nearly contiguous series of N-glycans from the soil nematodeCaenorhabditis elegans. Five major… Expand
  • figure 1
  • table I
  • table II
  • table III
  • figure 2
Highly Cited
1990
Highly Cited
1990
Deoxyfuconojirimycin (1,5-dideoxy-1,5-imino-L-fucitol) is a potent, specific and competitive inhibitor (Ki 1 x 10(-8) M) of human… Expand